<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>14 January 2014</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ProMetic</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">BioSciences</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> Ltd </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(BTO0012)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Declaration of interest</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">BioSciences</span><span style="font-family:'Times New Roman'; font-size:11pt"> Ltd has developed products and technology for the capture of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity from human blood and plasma products and as a consequence has a financial interest in </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> safety of blood products.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Executive Summary</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Calibri; font-size:11pt">-</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biosciences, in collaboration with the American Red Cross, has developed a technology based upon selective adsorption of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> proteins which enables the capture of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity from human blood and blood-derived components and products.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Calibri; font-size:11pt">-</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic’s</span><span style="font-family:'Times New Roman'; font-size:11pt">  technology, commonly referred to as </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> filtration, has been incorporated into a medical device (P-Capt™) developed in conjunction with and commercialized by </span><span style="font-family:'Times New Roman'; font-size:11pt">Macopharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> SA which provides increased blood safety by removal of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity (if present) from Red Blood Cell Concentrates (RBC). </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Calibri; font-size:11pt">-</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The P-Capt device obtained CE Mark approval in 2006, and since this time has been under evaluation by the UK’s National Blood Service (NHSBT) but never implemented.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Calibri; font-size:11pt">-</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The same technology, in a different format, has been used successfully by Swiss company </span><span style="font-family:'Times New Roman'; font-size:11pt">Octapharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> AG to provide an increased level of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> safety for virally-inactivated (S/D-treated) plasma for transfusion.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Octaplas</span><span style="font-family:'Times New Roman'; font-size:11pt"> LG™ manufactured using </span><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic’s</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> reduction technology has been approved for human administration in several countries including the UK. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Calibri; font-size:11pt">-</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In the absence of a commercial blood test with sufficient sensitivity and robustness for use in routine blood donor screening, the adoption of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> filtration would provide increased protection against the transmission of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> via blood and blood-derived products.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:Calibri; font-size:11pt">-</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> reduction technology constitutes a safe and proven approach to improving the safety of blood products independent of the availability of a </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> blood screening test.</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; list-style-position:inside; margin:5pt 2.25pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic</span><span style="font-family:'Times New Roman'; font-size:11pt"> Biosciences Ltd (PBL) is a UK based subsidiary of </span><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic</span><span style="font-family:'Times New Roman'; font-size:11pt"> Life Sciences Inc. a Canadian publicly traded corporation (TSX symbol: PLI; OTCQX: PFSCF) with globally recognized expertise in the purification of biological products, plasma-derived therapeutics and small-molecule drug development. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; list-style-position:inside; margin:0pt 2.25pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">PBL </span><span style="font-family:'Times New Roman'; font-size:11pt">specialises</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the development, manufacture and supply of purification materials and technologies for use in the manufacture of biopharmaceutical products. PBL’s purification products are used globally for the manufacture of therapeutic proteins and also form components of med</span><span style="font-family:'Times New Roman'; font-size:11pt">ical diagnosti</span><span style="font-family:'Times New Roman'; font-size:11pt">cs and medical devices. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; list-style-position:inside; margin:0pt 2.25pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In 2002 </span><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">established a joint venture company with the American Red Cross (called </span><span style="font-family:'Times New Roman'; font-size:11pt">Pathogen Removal and Diagnostic Technologies, Inc. (PRDT)) with the objective of </span><span style="font-family:'Times New Roman'; font-size:11pt">developing purification materials </span><span style="font-family:'Times New Roman'; font-size:11pt">with the ability to capture and remove </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> proteins from a wide variety of biological source materials including blood, red cells, plasma and plasma proteins. This approach was pursued because of the inherent difficulty in developing a diagnostic test for blood-borne </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity. Whilst a blood test is desirable as a means of distinguishing blood donors who are incubating </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> from those who are not, the incredibly small amount of infectious human </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> protein present in the blood of persons incubating </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> is extremely hard to detect, a situation </span><span style="font-family:'Times New Roman'; font-size:11pt">compounded by the highly complex nature of human blood that can mask the presence of trace contaminants. Currently </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> may only be identified reliably from examination of brain or nervous tissue once the disease has reached a relatively advanced stage and at this time no commercial assay has been developed which has been proven to possess the speed, sensitivity and robustness required for use as a routine blood screening assay. Consequently </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> filtration was pursued as this provides a means of increasing the safety of blood and plasma products without the need for a diagnostic test.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:5pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">PRDT, now a wholly owned subsidiary of PBL, successfully developed </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> removal technology based upon small synthetic compounds (</span><span style="font-family:'Times New Roman'; font-size:11pt">ligands</span><span style="font-family:'Times New Roman'; font-size:11pt">) attached to polymer supports which have the ability to bind to a wide variety of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> proteins including </span><span style="font-family:'Times New Roman'; font-size:11pt">misfolded</span><span style="font-family:'Times New Roman'; font-size:11pt"> human </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> protein (</span><span style="font-family:'Times New Roman'; font-size:11pt">PrPres</span><span style="font-family:'Times New Roman'; font-size:11pt">), the agent responsible for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">. The </span><span style="font-family:'Times New Roman'; font-size:11pt">PrioClear</span><span style="font-family:'Times New Roman'; font-size:11pt">™ line of affinity adsorbents has been extensively studied by </span><span style="font-family:'Times New Roman'; font-size:11pt">ProMetic</span><span style="font-family:'Times New Roman'; font-size:11pt"> and several independent parties, and has been shown to be efficacious and safe for use.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:5pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">PrioClear</span><span style="font-family:'Times New Roman'; font-size:11pt">™ </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> binding adsorbents capture both normal (</span><span style="font-family:'Times New Roman'; font-size:11pt">PrPc</span><span style="font-family:'Times New Roman'; font-size:11pt">) and abnormal/infectious (</span><span style="font-family:'Times New Roman'; font-size:11pt">PrPres</span><span style="font-family:'Times New Roman'; font-size:11pt">) forms in the presence of high concentrations of other proteins</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt">. The </span><span style="font-family:'Times New Roman'; font-size:11pt">PrioClear</span><span style="font-family:'Times New Roman'; font-size:11pt"> adsorbents have high affinity for </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> proteins and are capable of binding up to 6 logs of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity (ID</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:'Times New Roman'; font-size:11pt">) per milliliter of adsorbent. </span><span style="font-family:'Times New Roman'; font-size:11pt">PrioClear</span><span style="font-family:'Times New Roman'; font-size:11pt"> resins have been shown to provide &gt;4 log removal of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity from red blood cell concentrates</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> and to provide complete removal (to the limit of detection) of natural (endogenous) blood-borne </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">PBL has applied its </span><span style="font-family:'Times New Roman'; font-size:11pt">PrioClear</span><span style="font-family:'Times New Roman'; font-size:11pt">™ resins to a variety of commercial applications including the capture and removal of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> from </span><span style="font-family:'Times New Roman'; font-size:11pt">leucoreduced</span><span style="font-family:'Times New Roman'; font-size:11pt"> human red blood cell concentrate</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt">, the removal of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> from pooled virally inactivated SD plasma</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and the removal of </span><span style="font-family:'Times New Roman'; font-size:11pt">prions</span><span style="font-family:'Times New Roman'; font-size:11pt"> from plasma protein fractions and a variety of purified plasma protein products. </span><span style="font-family:'Times New Roman'; font-size:11pt">PrioClear</span><span style="font-family:'Times New Roman'; font-size:11pt"> A resin forms the active component of the P-Capt® filter developed jointly by PBL and French medical company </span><span style="font-family:'Times New Roman'; font-size:11pt">Macopharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> SA. P-Capt® is a CE Mark approved medical device for </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt">-filtration of </span><span style="font-family:'Times New Roman'; font-size:11pt">leucoreduced</span><span style="font-family:'Times New Roman'; font-size:11pt"> red cells. The P-Capt® filter has undergone extensive performance and safety testing</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt"> including clinical evaluations by the Irish</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and UK</span><a name="_ftnref8"></a><a href="#_ftn8">[8]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ftnref9"></a><a href="#_ftn9">[9]</a><span style="font-family:'Times New Roman'; font-size:11pt"> blood services and represents the world’s first </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt">-filtration product acknowledged to increase the safety of red blood cell concentrate. Since 2006, when it received its CE Mark, this product has been under evaluation by the UK’s National Blood Service (NHSBT). The adoption of the use of the filter was recommended by the UK’s Advisory Committee on the Safety of Blood, Tissues and Organs (</span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">) in October 2009 for “those not exposed to BSE through diet (</span><span style="font-family:'Times New Roman'; font-size:11pt">ie</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">those born after 1996)”. The recommendation was, however, removed in December 2012, according to </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTo</span><span style="font-family:'Times New Roman'; font-size:11pt">, due to a revised risk assessment model developed by the UK’s Department of Health</span><a name="_ftnref10"></a><a href="#_ftn10">[10]</a><span style="font-family:'Times New Roman'; font-size:11pt"> which assumes human blood contaminated with </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> is much less infectious than previously thought. In spite of recent findings that up to 1 in 2,000 of the UK population might be incubating </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> the model used to determine the cost effectiveness of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> safety measures has not been revised. Adoption of the P-Capt filter would increase the safety of blood products, as it adds an additional layer of protection by removing </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity present at very low levels, possibly even below the level of detection by the most advanced testing methodologies currently available when used in accordance with the manufacturers recommendations. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In collaboration with Swiss company </span><span style="font-family:'Times New Roman'; font-size:11pt">Octapharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> SA, a </span><span style="font-family:'Times New Roman'; font-size:11pt">PrioClear</span><span style="font-family:'Times New Roman'; font-size:11pt"> resin is currently used to provide an additional increase in safety for </span><span style="font-family:'Times New Roman'; font-size:11pt">Octapharma’s</span><span style="font-family:'Times New Roman'; font-size:11pt"> virally inactivated plasma product </span><span style="font-family:'Times New Roman'; font-size:11pt">Octaplas</span><span style="font-family:'Times New Roman'; font-size:11pt"> LG®</span><a name="_ftnref11"></a><a href="#_ftn11">[11]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ftnref12"></a><a href="#_ftn12">[12]</a><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Octaplas</span><span style="font-family:'Times New Roman'; font-size:11pt"> LG has received regulatory approval in over 11 countries to date, including the UK. In this format, the </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> removal technology is applied to plasma for transfusion, increasing the safety profile of this product with no reduction in product quality.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">In summary, there is a fully developed technology that can be implemented to increase the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">prion</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> safety of blood and blood-derived products in the UK. This technology has been available since 2006 and has been proven to be safe and efficacious.  It is used commercially in the case of S/D plasma, but not for red cells which represent a high risk in view of: (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">i</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">) the lack of a </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> screening assay for blood, (ii) the minimal processing performed on red cells (note </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">leucofiltration</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> is routinely performed in the UK and this may provide some protection against </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> but all </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">leucofilters</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> tested to date provide only partial removal of blood-borne </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">prion</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> infectivity), (iii) the unknown prevalence of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> in the UK population (current estimates suggest 1 in 2,000), (iv) the long incubation time (years or tens of years) before individuals incubating </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> show any symptoms and (v) the proven transmission of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> by transfusion of infected red cells.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:5pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:5pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt; text-align:justify"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> Reduction of TSE infectivity from human red blood cells using </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> protein affinity </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">ligands</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. L </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Gregori</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, BC Lambert, PV </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Gurgel</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, L </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Gheorghiu</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, P </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Edwardson</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, JT Lathrop, C </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">MacAuley</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, RG </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Carbonell</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, SJ Burton, D Hammond, RG </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Rohwer</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. Transfusion, 46: 1152-1161, 2006.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> Reduction in infectivity of endogenous transmissible spongiform </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">encephalopaties</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> present in blood by adsorption to selective affinity </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">ligands</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. L </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Gregori</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, PV </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Gurgel</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, JT Lathrop, P </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Edwardson</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, BC Lambert, RG </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Carbonell</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, SJ Burton, D Hammond, RG </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Rohwer</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">.  Lancet, 368: 2226-2230, 2006.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> removal effect of a specific affinity </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">ligand</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">OctaplasLG</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. A </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Neisser-Svae</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, A Bailey, L </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Gregori</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, A </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Heger</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, S Jordan, M </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Behizad</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, H </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Reichl</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, J </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Römisch</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, T-E </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Svae</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Vox</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Sanguinis</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, 97: 226-233, 2009.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> Removal of </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> infectivity by affinity </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">ligand</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> chromatography during </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">OctaplasLG</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> manufacturing – results from animal bioassay studies. A </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Heger</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, A Bailey, A </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Neisser-Svae</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, M </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Ertl</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, J </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Römisch</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, T-E </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Svae</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Vox</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Sanguinis</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, 102: 294-301, 2012.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> Infusion of P-Capt </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">neoantigen</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> formation. JA </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Cancelas</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, N </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Rugg</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, PG Pratt, DN </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Worsham</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, JC </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Pehta</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, K Banks, RD Davenport, WJ Judd. Transfusion, 51: 2228-2236, 2011.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> In vitro assessment of red-cell concentrates in SAG-M filtered through the </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">MacoPharma</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> P-CAPT </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">-reduction filter. CV Murphy, E Eakins, J Fagan, H </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Croxon</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, WG Murphy. Transfusion Medicine, 19: 109-116, 2009.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> Phase I/II safety study of transfusion of </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">-filtered red cell concentrates in transfusion-dependent patients. MR Cahill, T Murphy, M Kahn, J Fagan, WG Murphy. </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Vox</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Sanguinis</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, 99: 174-176, 2010.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt; text-align:justify"><a name="_ftn8"></a><a href="#_ftnref8">[8]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> Characteristics of </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">-filtered red cells suspended in pathogen-inactivated plasma (MB treated or solvent/detergent treated) for neonatal exchange transfusion. VS </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Hornsey</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, C Casey, K McColl, H Young, O Drummond, L McMillan, A Morrison, CV Prowse. </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Vox</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Sanguinis</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, 101: 28-34, 2011.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn9"></a><a href="#_ftnref9">[9]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> reduction of red blood cells: impact on component quality. M Wiltshire, S Thomas, J Scott, V Hicks, M Haines, P Cookson, M Garwood, R Cardigan.  Transfusion, 50: 970-979, 2010.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn10"></a><a href="#_ftnref10">[10]</a><span style="font-family:'Times New Roman'; font-size:10pt"> </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/212250/SaBTO_10_Dec_2012_final.zip"><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/212250/SaBTO_10_Dec_2012_final.zip</span></a></p><p style="margin:0pt; text-align:justify"><a name="_ftn11"></a><a href="#_ftnref11">[11]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> Safety of a universal, virus-inactivated and </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">-depleted pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. P </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Jilma-Stohlawetz</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, FW </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Kursten</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, C </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Walasek</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, M Horvath, G </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Leitner</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, J List, P </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Quehenberger</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, M </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Schwameis</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, J </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Bartko</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, B </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Jilma</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. Transfusion, 51: 1228-1240, 2011.</span></p><p style="margin:0pt; text-align:justify"><a name="_ftn12"></a><a href="#_ftnref12">[12]</a><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> The effect of </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">prion</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> reduction in solvent/detergent-treated plasma on haemostatic variables. AS </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Lawrie</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, L Green, MT </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Canciani</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, IJ Mackie, F </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Peyvandi</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, MA Scully, SJ </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Machin</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">. </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Vox</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">Sanguinis</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">, 99: 232-238, 2010.</span></p></body></html>